Skip to main
  1. Stocks
  2. Spruce Biosciences Inc
  3. Forecast
SPRB

SPRB Stock Forecast & Price Target

SPRB Analyst Ratings

Based on 9 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Spruce Biosciences is supported by a compelling regulatory and clinical setup for TA-ERT, with FDA commentary reinforcing flexibility in rare diseases and a clear path toward its expected 4Q26 BLA submission. The company’s lead program addresses a severe unmet need in MPS IIIB, and its evidence package combines biomarker reduction in CSF heparan sulfate with longer-term neurodevelopmental and imaging data, while competitors remain several years behind and mostly early-stage. Financially, the stock appears mispriced versus the ~$60M EV and ~$130M market cap, especially with $96M in cash providing runway into 2H27, a ~$150M+ PRV opportunity, and modeled peak sales above $300M.

Bears say

Spruce Biosciences is a development-stage biotech with a very limited pipeline, leaving valuation heavily dependent on TA-ERT for MPS IIIB while SPR202 remains only in preclinical development. Its negative outlook is driven by major clinical and regulatory uncertainty, since no approved MPS IIIB therapies exist and approval may hinge on Phase 2 surrogate biomarker data rather than definitive outcomes, while weekly intracerebroventricular dosing could also constrain adoption. Financially, the company reported 2Q26 OpEx of $17M, a net loss of $16M, and a per-share loss of ($6.68), and it is expected to keep burning cash and likely raise additional capital, creating dilution risk for shareholders.

SPRB has been analyzed by 9 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

SPRB Analyst Forecast & Price Prediction

Get the latest SPRB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SPRB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Spruce Biosciences Inc (SPRB) Forecast

Analysts have given SPRB a Strong Buy based on their latest research and market trends.

According to 9 analysts, SPRB has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $158.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $158.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Spruce Biosciences Inc (SPRB)


SPRB Analyst Forecast & Price Prediction

Get the latest SPRB stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in SPRB

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover SPRB stock data and trends